Earticle

현재 위치 Home

신증후군 환아에 대한 Deflazacort의 효과와 안전성
Efficacy and Safety of Deflazacort in Korean Children with Nephrotic Syndrome

첫 페이지 보기
  • 발행기관
    한국임상약학회 바로가기
  • 간행물
    한국임상약학회지 바로가기
  • 통권
    제10권 제2호 (2000.09)바로가기
  • 페이지
    pp.51-56
  • 저자
    김미정, 이숙향, 전계원, 진동규
  • 언어
    한국어(KOR)
  • URL
    https://www.earticle.net/Article/A91283

※ 기관로그인 시 무료 이용이 가능합니다.

4,000원

원문정보

초록

영어
Deflazacort, an oxazoline derivative of prednisolone, has been claimed to have anti-inflammatory effects with fewer side effects compared to prednisone. The objectives of the study were to evaluate efficacy and safety of deflazacort in children with nephrotic syndrome. Eligible Patients were the children with nephrotic syndrome who were treated with deflazacort from October. 1994 to April. 1999. Nephrotic syndrome was defined as having albumin level of less than 2.5 mg/dL and 24-hour urinary protein excretion of greater than . The primary parameters evaluating the efficacy of deflazacort were response rate, time to respond and relapse frequency. The safety profiles were the impact on children's growth, calcium sparing effect, glucose metabolism, lipid profile and adverse drug reactions. As results, total of 60 children were evaluated (47 boys, 13 girls). Response rate was (57/60) for initial and late responders. Median time to respond was 12 days (range 7-110 days) and median relapse frequency was one time (range 0-6). Weight/height ratio increased from (p<0.001) and plasma calcium level, from after treatment (p<0.001). Change of fasting glucose level was not statistically significant , while change of total cholesterol was significant , p<0.001). In conclusion, patients on deflazacort showed similar efficacy in treatment of nephrotic syndrome as reported for prednisone with less impact on growth inhibition and metabolic side effects of hyperglycemia and hyperlipidemia.

키워드

Nephrotic Syndrome (NS); Deflazacort

저자

  • 김미정 [ Kim, Mi Jeong | 숙명여자대학교 임상약학대학원(Graduate School of Clinical Pharmacy Sookmyung Women's University) ]
  • 전계원 [ Jeon, Kye Won | 삼성서울병원 소아과(Department of Pediatrics, Samsung Medical Center) ]
  • 진동규 [ Jin, Dong Kyu | 삼성서울병원 소아과(Department of Pediatrics, Samsung Medical Center) ]
  • 이숙향 [ Lee, Suk Hyang | 숙명여자대학교 임상약학대학원(Graduate School of Clinical Pharmacy Sookmyung Women's University) ]

참고문헌

자료제공 : 네이버학술정보

간행물 정보

발행기관

  • 발행기관명
    한국임상약학회 [Korean College of Clinical Pharmacy]
  • 설립연도
    1
  • 분야
    의약학>약학
  • 소개
    합리적 약물치료(rational pharmacotherapy)의 보장 및 증진을 궁극목적으로 하며 이를 달성하기 위해 임상약학의 발전과 회원 상호간의 친목을 도모한다.

간행물

  • 간행물명
    한국임상약학회지 [Korean Journal of Clinical Pharmacy]
  • 간기
    계간
  • pISSN
    1226-6051
  • 수록기간
    1991~2026
  • 등재여부
    KCI 등재
  • 십진분류
    KDC 518 DDC 615

이 권호 내 다른 논문 / 한국임상약학회지 제10권 제2호

    피인용수 : 0건 (자료제공 : 네이버학술정보)

    함께 이용한 논문 이 논문을 다운로드한 분들이 이용한 다른 논문입니다.

      출처 : 네이버학술정보

        0개의 논문이 장바구니에 담겼습니다.

        페이지 저장
        소속기관 조회
        이용자님의 소속기관(단체)이 서비스에 가입되어 있는지 확인해 보십시오.
        기관회원에 소속되어 있는 이용자는 원문을 무료로 이용할 수 있습니다.